Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice.

Inflammatory bowel disease (IBD) results from dysregulation of intestinal mucosal immune responses to microflora in genetically susceptible hosts. A major challenge for IBD research is to develop new strategies for treating this disease. Berberine, an alkaloid derived from plants, is an alternative medicine for treating bacterial diarrhea and intestinal parasite infections. Recent studies suggest that berberine exerts several other beneficial effects, including inducing anti-inflammatory responses. This study determined the effect of berberine on treating dextran sulfate sodium (DSS)-induced intestinal injury and colitis in mice. Berberine was administered through gavage to mice with established DSS-induced intestinal injury and colitis. Clinical parameters, intestinal integrity, proinflammatory cytokine production, and signaling pathways in colonic macrophages and epithelial cells were determined. Berberine ameliorated DSS-induced body weight loss, myeloperoxidase activity, shortening of the colon, injury, and inflammation scores. DSS-upregulated proinflammatory cytokine levels in the colon, including TNF, IFN-γ, KC, and IL-17 were reduced by berberine. Berberine decreased DSS-induced disruption of barrier function and apoptosis in the colon epithelium. Furthermore, berberine inhibited proinflammatory cytokine production in colonic macrophages and epithelial cells in DSS-treated mice and promoted apoptosis of colonic macrophages. Activation of signaling pathways involved in stimulation of proinflammatory cytokine production, including MAPK and NF-κB, in colonic macrophages and epithelial cells from DSS-treated mice was decreased by berberine. In summary, berberine promotes recovery of DSS-induced colitis and exerts inhibitory effects on proinflammatory responses in colonic macrophages and epithelial cells. Thus berberine may represent a new therapeutic approach for treating gastrointestinal inflammatory disorders.

[1]  Jie-shou Li,et al.  Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. , 2011, The Journal of infectious diseases.

[2]  V. Young,et al.  Microbial ecology of the murine gut associated with the development of dextran sodium sulfate‐induced colitis , 2011, Inflammatory bowel diseases.

[3]  Jianping Ye,et al.  Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis , 2011, PloS one.

[4]  Min Zhang,et al.  Evidence for the complementary and synergistic effects of the three-alkaloid combination regimen containing berberine, hypaconitine and skimmianine on the ulcerative colitis rats induced by trinitrobenzene-sulfonic acid. , 2011, European journal of pharmacology.

[5]  Dong-Hyun Kim,et al.  Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-κB activation. , 2010, European journal of pharmacology.

[6]  M. Zeitz,et al.  TNFα-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFκB signaling , 2010, Journal of Cell Science.

[7]  Lori A. Coburn,et al.  The Apolipoprotein E-Mimetic Peptide COG112 Inhibits NF-κB Signaling, Proinflammatory Cytokine Expression, and Disease Activity in Murine Models of Colitis* , 2010, The Journal of Biological Chemistry.

[8]  R. Pi,et al.  Berberine Attenuates Experimental Autoimmune Encephalomyelitis in C57 BL/6 Mice , 2010, PloS one.

[9]  Chih-Hsin Tang,et al.  Berberine suppresses neuroinflammatory responses through AMP‐activated protein kinase activation in BV‐2 microglia , 2010, Journal of cellular biochemistry.

[10]  Qiurong Li,et al.  Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  Jian Xiao,et al.  Berberine Inhibits HIV Protease Inhibitor-Induced Inflammatory Response by Modulating ER Stress Signaling Pathways in Murine Macrophages , 2010, PloS one.

[12]  R. Blumberg.  Inflammation in the Intestinal Tract: Pathogenesis and Treatment , 2009, Digestive Diseases.

[13]  Guoliang Cui,et al.  Berberine Differentially Modulates the Activities of ERK, p38 MAPK, and JNK to Suppress Th17 and Th1 T Cell Differentiation in Type 1 Diabetic Mice* , 2009, The Journal of Biological Chemistry.

[14]  J. B. Kim,et al.  Berberine suppresses proinflammatory responses through AMPK activation in macrophages. , 2009, American journal of physiology. Endocrinology and metabolism.

[15]  B. Aggarwal,et al.  Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. , 2008, Cancer research.

[16]  D. Artis.  Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut , 2008, Nature Reviews Immunology.

[17]  A. Baldwin,et al.  Loss of Epithelial RelA Results in Deregulated Intestinal Proliferative/Apoptotic Homeostasis and Susceptibility to Inflammation1 , 2008, The Journal of Immunology.

[18]  R. Xavier,et al.  Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.

[19]  P. Rutgeerts,et al.  American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. , 2007, Gastroenterology.

[20]  H. Algood,et al.  l-Arginine Availability Regulates Inducible Nitric Oxide Synthase-Dependent Host Defense against Helicobacter pylori , 2007, Infection and Immunity.

[21]  M. Neurath,et al.  Epithelial NEMO links innate immunity to chronic intestinal inflammation , 2007, Nature.

[22]  P. Mannon,et al.  The fundamental basis of inflammatory bowel disease. , 2007, The Journal of clinical investigation.

[23]  M. Washington,et al.  Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. , 2007, Gastroenterology.

[24]  N. Van Rooijen,et al.  Suppression of experimental colitis by intestinal mononuclear phagocytes , 2006, Journal of leukocyte biology.

[25]  Jason M Doherty,et al.  Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Satoru Inaba,et al.  Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins , 2004, Nature Medicine.

[27]  S. Akira,et al.  Toll-like receptors in innate immunity. , 2004, International immunology.

[28]  Y. Kano,et al.  Pharmacological properties of traditional medicine (XXIX): effect of Hange-shashin-to and the combinations of its herbal constituents on rat experimental colitis. , 2004, Biological & pharmaceutical bulletin.

[29]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[30]  Y. Tabata,et al.  Elimination of Local Macrophages in Intestine Prevents Chronic Colitis in Interleukin-10-Deficient Mice , 2003, Digestive Diseases and Sciences.

[31]  M. Büchler,et al.  Characterisation of Acute Murine Dextran Sodium Sulphate Colitis: Cytokine Profile and Dose Dependency , 2000, Digestion.

[32]  S. Mineshita,et al.  The effect of berberine chloride on experimental colitis in rats in vivo and in vitro. , 2000, The Journal of pharmacology and experimental therapeutics.

[33]  X. Yao,et al.  Vasorelaxant and antiproliferative effects of berberine. , 2000, European journal of pharmacology.

[34]  Garside.  Cytokines in experimental colitis , 1999, Clinical and experimental immunology.

[35]  S. Kitajima,et al.  Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. , 1999, Experimental animals.

[36]  E. Bloemena,et al.  Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines , 1998, Clinical and experimental immunology.

[37]  A. Grönberg,et al.  Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: Effects in CD4+-cell depleted, athymic and NK-cell depleted SCID mice , 1996, Inflammation Research.

[38]  C. Elson,et al.  Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. , 1994, Gastroenterology.

[39]  T. Ohkusa,et al.  A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice , 1990 .

[40]  R. Sack,et al.  Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins , 1982, Infection and immunity.

[41]  T. Subbaiah,et al.  Berberine sulfate: antimicrobial activity, bioassay, and mode of action. , 1969, Canadian journal of microbiology.

[42]  G. Trinchieri,et al.  Innate immune mechanisms of colitis and colitis-associated colorectal cancer , 2011, Nature Reviews Immunology.

[43]  Chen Dong,et al.  MAP kinases in the immune response. , 2002, Annual review of immunology.

[44]  R. Blumberg,et al.  The immunology of mucosal models of inflammation. , 2002, Annual review of immunology.

[45]  R. Ulevitch,et al.  Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. , 1995, Annual review of immunology.

[46]  M. Torii,et al.  In vitro effects of berberine sulphate on the growth and structure of Entamoeba histolytica, Giardia lamblia and Trichomonas vaginalis. , 1991, Annals of tropical medicine and parasitology.